Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review

This narrative review discusses the advancements in the management of alopecia areata (AA), an autoimmune hair loss condition, through new targeted therapies such as biologics and small molecules. These therapies have transformed the treatment landscape for AA, offering new benefits but also presenting challenges and uncertainties. The review highlights the importance of real-world data collection and introduces GRASS-UK/GRASS-International, a global network of disease registers aimed at studying the long-term safety and effectiveness of these emerging therapies. The review underscores the need for ongoing research and collaboration to optimize AA management and address future challenges.

The narrative review explores the evolving treatment landscape for alopecia areata (AA), emphasizing the role of Janus kinase (JAK) inhibitors like baricitinib, ritlecitinib, and deuruxolitinib, which have shown promise in clinical trials, such as the BRAVE-AA1 and BRAVE-AA2 trials involving about 1,200 participants. These therapies represent a shift from traditional treatments with limited efficacy. The review underscores the importance of real-world data (RWD) and disease registries, like GRASS-International, for assessing long-term safety and effectiveness. It also highlights the psychological impact of AA and the need for comprehensive care, including mental health support. Future challenges include optimizing treatment strategies, understanding long-term safety, and addressing the emotional burden on patients.